Chronic Obstructive Pulmonary Disease: Emerging Medical Therapies

Author: MacIntyre, Neil R.

Source: Respiratory Care, Volume 49, Number 1, January 2004 , pp. 64-71(8)

Publisher: The Journal Respiratory Care Company

Buy & download fulltext article:

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Abstract:

As many as 10 million Americans have chronic obstructive pulmonary disease and as a consequence experience disabling symptoms, high cost of care, and substantial mortality. Several new approaches are being investigated for possible benefit in managing (or even reversing) chronic obstructive pulmonary disease. This article reviews 4 new approaches that are either in or close to phase III trials: long-acting bronchodilators, phosphodiesterase-4 inhibitors, vasodilators, and retinoids. Of those tiotropium appears to be the closest to receiving clinical approval in the United States. The risk/benefit ratio and the cost-effectiveness of the other compounds are less clear and await additional study.

Keywords: CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COPD; BRONCHODILATOR; PHOSPHODIESTERASE INHIBITOR; VASODILATOR; RETINOID; RETINOIC ACID

Document Type: Research article

Affiliations: 1: Respiratory Care Services, PO Box 3911, Duke University Medical Center, Durham NC 27710;, Email: neil.macintyre@duke.edu

Publication date: 2004-01-01

More about this publication?

As of January 1, 2013, Respiratory Care content will no longer be hosted on ingentaconnect. Please contact the publisher at info@aarc.org for information on how to continue access to this title.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Membership Information
Information for Advertisers
Podcasts
Clinical Practice Guidelines
Past OPEN FORUM Abstracts
ingentaconnect is not responsible for the content or availability of external websites